Chief, Solid Organ Transplant Infectious Diseases Service
Assistant Professor of Medicine
725 West Lombard Street Baltimore, MD 21201
Education and Training
Bachelor of Arts (B.A): Biology and English, The Johns Hopkins University, Baltimore, MD
Master's in Public Health (M.P.H): Public Health Leadership, University of North Carolina School of Public Health, Chapel Hill, NC
Doctor of Medicine (M.D): Duke University School of Medicine, Durham, NC
Residency: Internal Medicine/Pediatrics, Yale-New Haven Hospital, New Haven, CT
Fellowship: Infectious Diseases, University of Maryland Medical Center, Baltimore, MD
Post-Doctoral Fellowship: Immunology Laboratory, Vaccine Research Center, National Institutes of Health, Bethesda, MD
Dr. Saharia received his medical degree from Duke University School of Medicine. He completed his residency training in Internal Medicine-Pediatrics at Yale-New Haven Hospital and served as Chief Resident for Internal Medicine-Pediatrics in his fourth year. Following residency, Dr. Saharia completed a Fellowship in Infectious Diseases at the University of Maryland Medical Center. Dr. Saharia then joined the Immunology Laboratory at the Vaccine Research Center, NIH as a post-doctoral fellow under the mentorship of Dr. Richard Koup, where he used multiparameter flow cytometry and intracellular cytokine staining techniques to identify phenotypic and functional characteristics of Mycobacterium tuberculosis-specific CD4 T cells that could discriminate between various stages of infection.
Dr. Saharia joined the Institute of Human Virology in 2012 as Assistant Professor of Medicine. He provides consultation services on the Transplant Infectious Disease Service and serves as Chief of the Transplant Infectious Disease section(2017). His practice focuses on the care of pre- and post-solid organ transplant recipients with infectious concerns, patients with infected mechanical cardiac devices (including patients on ECMO), and persons infected with HIV.
Dr. Saharia's research interests include infectious outcomes in solid organ transplant recipients and the diagnosis and treatment of mycobacterial infections, including tuberculosis. He has been involved in NIH-sponsored and industry-sponsored clinical trials.
Infectious outcomes in transplant recipients, mycobacterial infections, HIV, clinical trials
Atanackovic D, Luetkens T, Omili D, Iraguha T, Lutfi F, Hardy NM, Fan X, Saharia KK, Husson JS, Niederhaus SV, Margiotta PJ, Lee ST, Law JY, Mannuel HD, Vander Mause E, Bauman S, Lesho P, Hankey KG, Baddley JW, Kocoglu MH, Yared JA, Rapoport AP, Dahiya S. Vaccine-induced T cells against Sars-Cov-2 and its Omicron variant in B cell-depleted lymphoma patients after CART. Blood. 2022 May 10:blood.2022016175. doi: 10.1182/blood.2022016175. Epub ahead of print. PMID: 35537186; PMCID: PMC9135504.
Saharia KK, Husson JS, Niederhaus SV, et al. Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine. Clin Transl Immunology. 2022;11(5):e1391. Published 2022 Apr 29. doi:10.1002/cti2.1391
Shishido AA, Noe M, Saharia K, Luethy P. Clinical impact of a metagenomic microbial plasma cell-free DNA next-generation sequencing assay on treatment decisions: a single-center retrospective study. BMC Infect Dis. 2022;22(1):372. Published 2022 Apr 13. doi:10.1186/s12879-022-07357-8
Saharia KK, Anjan S, Streit J, et al. Clinical characteristics of COVID-19 in solid organ transplant recipients following COVID-19 vaccination: A multicenter case series. Transpl Infect Dis. 2022;24(2):e13774. doi:10.1111/tid.13774
Prakash K, Chandorkar A, Saharia KK. Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update. Diagnostics (Basel). 2021;11(5):875. Published 2021 May 13. doi:10.3390/diagnostics11050875
Saharia KK, Petrovas C, Ferrando-Martinez S, Leal M, Luque R, Ive P, Luetkemeyer A, Havlir D, Koup RA. Tuberculosis therapy modifies the cytokine profile, maturation state, and expression of inhibitory molecules on Mycobacterium tuberculosis-specific CD4+ T-cells. PLoS One. 2016; 11 (7): e0158262.
Herrin DM, Coates EE, Costner PJ, Kemp TJ, Nason MC, Saharia KK, Pan Y, Sarwar UN, Holman L, Yamshchikov G, Koup RA, Pang YY, Seder RA, Schiller JT, Graham BS, Pinto LA, Ledgerwood JE. Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus. Hum Vaccin Immunother. 2014;10(12):3446-54.
Saharia KK, Koup RA. T cell susceptibility to HIV influences outcome of opportunistic infections. Cell. 2013;155(3):505-14.